ACUSON Sequoia Diagnostic Ultrasound System, ACUSON Sequoia Select Diagnostic Ultrasound System, ACUSON Origin Diagnostic Ultrasound System

The ACUSON Sequoia, Sequoia Select, and Origin systems are advanced diagnostic ultrasound platforms designed to provide comprehensive imaging across multiple clinical specialties, with significant enhancements focused on cardiac assessment, workflow optimization, and expanded diagnostic capabilities like hepatic fat quantification. These systems achieve their purpose by integrating a wide array of ultrasound modalities (B-mode, Doppler, elastography, 3D/4D imaging), specialized transducers including an intracardiac echocardiography (ICE) catheter, and sophisticated artificial intelligence-driven software algorithms, validated on patient data, for automated anatomical feature recognition, image optimization, and quantitative measurement assistance.

The ACUSON Sequoia, Sequoia Select, and Origin are mobile, software-controlled diagnostic ultrasound systems designed for a broad range of clinical applications including fetal, abdominal, pediatric, OB/GYN, cardiac, vascular, and musculoskeletal imaging. These systems function by transmitting and receiving ultrasound echo data, which is then processed to display images in various modes such as B-Mode, M-Mode, Pulsed and Continuous Wave Doppler, Color Doppler, 3D/4D Volume Imaging, Contrast Agent Imaging, and Elastography (Strain Imaging and Shear Wave Elastography). The systems also support anatomical measurements and calculation packages to aid clinicians in diagnosis. The ACUSON Sequoia and Sequoia Select models additionally feature an Ultrasonically-Derived Fat Fraction (UDFF) tool to assist in managing adult patients with hepatic steatosis. Key modifications enhance these systems with new software applications leveraging Artificial Intelligence and Machine Learning, notably AI Measure, AI Assist, 2D HeartAI, and 4D HeartAI. These tools are primarily designed to improve cardiac imaging workflows by automating measurements of blood flow, valves, and anatomical features, with validation testing on patient datasets demonstrating high success rates (e.g., AI Assist successful placement >92% for any placement location, AI Measure success >88%) and strong correlations with expert-derived reference standards (e.g., Pearson correlation ≥0.81 for 2D HeartAI). The systems also incorporate new transducers like the Z6T, 5Z1, and the AcuNav Lumos 4D ICE catheter, facilitating expanded clinical applications such as transesophageal and intracardiac imaging, the latter for guiding percutaneous cardiac interventions with the ACUSON Origin. Nonclinical evaluations confirmed conformity to safety standards for acoustic output, biocompatibility, and electrical/mechanical integrity.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How do the AI-driven features (AI Measure, AI Assist, 2D HeartAI, 4D HeartAI) perform in diverse patient populations with varying body habitus and cardiac pathologies beyond the tested demographics?; What is the quantifiable impact of AI Assist on sonographer workflow efficiency and reduction in inter-operator variability for cardiac assessments?; How does the accuracy of the Ultrasonically-Derived Fat Fraction (UDFF) tool compare to established methods like MRI-PDFF or liver biopsy for quantifying hepatic steatosis in a broader clinical cohort?; What are the specific image quality or diagnostic advantages offered by the new Z6T and 5Z1 transducers, as well as the AcuNav Lumos 4D ICE catheter, compared to their predecessors or alternatives in their intended cardiac applications?; Could the "truthing" process for the AI algorithms, relying on a mean from three examiners or expert scoring, introduce any systematic bias, and what measures were taken to ensure robustness across different levels of operator expertise?